The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases

Toldo, Stefano; Abbate, Antonio

doi:10.1038/s41569-023-00946-3

Cited by 63 publications

(15 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Typical examples of diseases attributed to autoinflammatory mechanisms encompass familial Mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), and cryopyrin-associated periodic syndromes (CAPS) [ 1 , 5 , 9 , 52 , 53 ]. The common denominator of the latter disorders is an exaggerated production of IL-1 due to a dysregulated activation of the NLRP3 inflammasome [ 1 , 5 , 9 , 50 , 54 , 55 , 56 , 57 ].…”

Section: Pathophysiology Of Recurrent Pericarditismentioning

confidence: 99%

“…[ 58 ]. The NLRP3 inflammasome, through its main product, IL-1β, plays a central role in clinical manifestations [ 1 , 5 , 9 , 50 , 54 , 55 , 56 , 57 , 58 ].…”

Section: Pathophysiology Of Recurrent Pericarditismentioning

confidence: 99%

“…Its activation promotes the release of IL-1β. IL-1 subtypes then activate the IL-1 receptor, resulting in an enhanced inflammatory response [ 1 , 5 , 9 , 50 , 54 , 55 , 56 , 57 , 58 , 61 , 62 ].…”

Section: Pathophysiology Of Recurrent Pericarditismentioning

confidence: 99%

See 2 more Smart Citations

Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis

Lazarou,

Koutsianas,

Theofilis

et al. 2024

Life

View full text Add to dashboard Cite

Recurrent pericarditis is a problematic clinical condition that impairs the quality of life of the affected patients due to the need for repeated hospital admissions, emergency department visits, and complications from medications, especially glucocorticoids. Unfortunately, available treatments for recurrent pericarditis are very limited, including only a handful of medications such as aspirin/NSAIDs, glucocorticoids, colchicine, and immunosuppressants (such as interleukin-1 (IL-1) blockers, azathioprine, and intravenous human immunoglobulins). Until recently, the clinical experience with the latter class of medications was very limited. Nevertheless, in the last decade, experience with IL-1 blockers has consistently grown, and valid clinical data have emerged from randomized clinical trials. Accordingly, IL-1 blockers are a typical paradigm shift in the treatment of refractory recurrent pericarditis with a clearly positive cost/benefit ratio for those unfortunate patients with multiple recurrences. A drawback related to the above-mentioned medications is the absence of universally accepted and established treatment protocols regarding the full dose administration period and the need for a tapering protocol for individual medications. Another concern is the need for long-standing treatments, which should be discussed with the patients. The above-mentioned unmet needs are expected to be addressed in the near future, such as further insights into pathophysiology and an individualized approach to affected patients.

show abstract

Section: Pathophysiology Of Recurrent Pericarditismentioning

confidence: 99%

“…[ 58 ]. The NLRP3 inflammasome, through its main product, IL-1β, plays a central role in clinical manifestations [ 1 , 5 , 9 , 50 , 54 , 55 , 56 , 57 , 58 ].…”

Section: Pathophysiology Of Recurrent Pericarditismentioning

confidence: 99%

See 1 more Smart Citation

Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis

Lazarou,

Koutsianas,

Theofilis

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…1 Acute injury to the heart, such as an acute myocardial infarction, induces a local and systemic inflammatory response. 2,3 In autoimmune disease, persistent, unresolving inflammation causes injury to the cardiovascular structures. 4 In a few instances, the causes for injury or inflammation are obvious, ie, acute myocardial infarction, whereas in most cases, the causes of low-grade chronic smoldering inflammation or nonresolving inflammation are not known.…”

mentioning

confidence: 99%

“…The clinical trials with canakinumab and colchicine demonstrate that targeting inflammation with an IL-1β blocker (canakinumab) or an inhibitor of tubulin polymer formation and nonselective inflammasome inhibitor (colchicine) prevents recurrent atherothrombotic events. 2,3 In this issue, Jaffree et al 13 from Richmond, VA, address the central role of IL-1 in the development and progression of heart failure. A subanalysis of the canakinumab trial and several phase II trials with anakinra, a recombinant IL-1 receptor antagonist, demonstrate that blocking IL-1 has beneficial effects in heart failure.…”

mentioning

confidence: 99%

Inflammation and Heart Diseases: Immunology, Cardiology, and Rheumatology

Abbate,

Weber,

Garschick

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Disclosures: A. Abbate has received research support or consultant fees from CardiolRx, Implicit Biosciences, Kiniksa, Novo Nordisk, and Olatec; B. Weber reports scientific advisory board fees from Novo Nordisk, Kiniksa Pharmaceuticals, and Horizon Therapeutic. M. Garschick reports consultant fees for Kiniska, Agepha, BMS, and Horizon Therapeutics. L. Adamo has received consultant fees from Kiniksa and is co-founder of i-Cordis, LLC. C. Beavers has nothing to disclose.

show abstract

Coordination‐Driven Nanomedicine Mitigates One‐Lung Ventilation‐Induced Lung Injury via Radicals Scavenging and Cell Pyroptosis Inhibition

Fan,

Ou,

Xiao

et al. 2024

Small

View full text Add to dashboard Cite

One‐lung ventilation (OLV) during thoracic surgery often leads to post‐operative complications, yet effective pharmacological interventions are lacking. This study reports a baicalin‐based metal‐coordination nanomedicine with disulfiram (DSF) co‐loading to address one‐lung ventilation‐induced lung injury and reperfusion injury (OLV‐LIRI). Baicalin, known for its robust antioxidant properties, suffers from poor water solubility and stability. Leveraging nanotechnology, baicalin's coordination is systematically explored with seven common metal ions, designing iron/copper‐mediated binary coordination nanoparticles to overcome these limitations. The self‐assembled nanoparticles, primarily formed through metal coordination and π–π stacking forces, encapsulated DSF, ensuring high colloidal stability in diverse physiological matrices. Upon a single‐dose administration via endotracheal intubation, the nanoparticles efficiently accumulate in lung tissues and swiftly penetrate the pulmonary mucosa. Intracellularly, baicalin exhibits free radical scavenging activity to suppress inflammation. Concurrently, the release of Cu2+ and DSF enables the in situ generation of CuET, a potent inhibitor of cell pyroptosis. Harnessing these multifaceted mechanisms, the nanoparticles alleviate lung injury symptoms without notable toxic side effects, suggesting a promising preventive strategy for OLV‐LIRI.

show abstract

The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases

Cited by 63 publications

References 195 publications

Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis

Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis

Inflammation and Heart Diseases: Immunology, Cardiology, and Rheumatology

Coordination‐Driven Nanomedicine Mitigates One‐Lung Ventilation‐Induced Lung Injury via Radicals Scavenging and Cell Pyroptosis Inhibition

Contact Info

Product

Resources

About